Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery

Save

Report Abuse

Description

The primary study objective is to compare the effectiveness of the combination of phacoemulsification with intraocular lens implant with ELIOS or iStent inject W in reducing IOP at 12 months postoperatively.

Targeted Conditions

Study Overview

Start Date
December 5, 2023
Completion Date
June 30, 2026
Enrollment
194
Date Posted
February 7, 2024
Accepts Healthy Volunteers?
No
Gender
All

Locations

Full Address
ELIOS Clincal Site
Madrid, Spain

Eligibility

Minimum Age (years)
40
Eligibility Criteria
Inclusion Criteria:

Male or female subjects.
40 years old or older.
Diagnosis of mild to moderate primary open-angle glaucoma, pseudoexfoliation glaucoma or pigmentary glaucoma:
Visually significant cataract eligible for phacoemulsification.

Exclusion Criteria:

All forms of angle closure glaucoma
Secondary glaucoma, including traumatic, neovascular, uveitic, lens-induced, steroid-induced, angle-recession, glaucoma associated with vascular disorders, and glaucoma associated with increased episcleral venous pressure
Congenital or developmental glaucoma
Prior incisional glaucoma surgery, intraocular surgery or ocular laser treatment of any type with the exception of selective laser trabeculoplasty (SLT) occurring a minimum of 6 months prior to the Screening visit

Study Contact Info

Study Contact Name
Amandine Jacques
Study Contact Email
Study Contact Phone

Contact Listings Owner Form

Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
No
FDA Regulated Device?
No
NCTid (if applicable)
NCT06246136